GelSana engineers highly elastic wound dressing polymers which stretch and conform across any wound, reduce inflammation through polymer chemistry, prevent infection, and provide sustained drug delivery over time.

RheumaGen is a cell and gene therapy company developing therapies with the potential to cure rheumatoid arthritis (RA) and other major autoimmune diseases like multiple sclerosis (MS), juvenile diabetes (T1D), ankylosing spondylitis, and celiac disease.

Vona Oncology: Providing New Hope for Patients with Aggressive Cancers What the Company Does Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer, and melanoma. Vona Oncology has an innovative, novel small molecule that is very efficacious with little toxicity to improve standard of care. Current Landscape About 20 percent of women diagnosed with breast cancer are triple negative, which means therapy options with targeted drugs are very limited. TNBC is often diagnosed in younger women, at very advanced stages with high likelihood of relapse...

Atara Biotherapeutics is on a mission to “unleash the natural power of the body’s immune system by harnessing the compelling biological features of T cells—the immune system's most effective weapon in fighting disease.” The Atara site at Fitzsimons Innovation Community is a world-class manufacturing facility with a research and development focus. Atara’s expertise, talent, and track record of firsts elevate Colorado’s presence as a cell and gene therapy hub.

For more than two decades, ClinImmune Cell & Gene Therapy at Fitzsimons Innovation Community has been blazing trails in the field of organ and stem cell transplantation. The organization’s unique approach to leveraging its leadership position contributes to Colorado’s momentum in this growing space.

Fitzsimons Innovation Community Wins CBSA Building Momentum Award Fitzsimons Innovation Community is the inaugural recipient of the Colorado BioScience Association’s new Award: Building Momentum. This award recognizes investments an honoree is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth. Expansion and growth are just part of the story here. It’s about supporting people, fostering connections, and creating an environment that helps spark discoveries. April Giles, Fitzsimons Innovation Community Vice President of Business, answers key questions about the momentum building at Fitzsimons Innovation Community. Q: Tell us more about the momentum building at Fitzsimons...